This website is intended for Healthcare Professionals. If you are not a Healthcare Professional please click here
Prescribing
Information

Innovative inhalers

An inhaler that is propellant free based on innovative inhaler technology
EXPLORE

EXPLORE

respimat seperator

Spiolto® Respimat® (tiotropium & olodaterol)

What Spiolto® Respimat® is and what it is used for

spiolto

What Spiolto® Respimat® is

Spiolto® Respimat® contains two active substances called tiotropium and olodaterol. These belong to a group of medicines called long-acting bronchodilators. Tiotropium belongs to the subgroup of anticholinergics; olodaterol belongs to the subgroup of long acting beta2 agonists

What Spiolto® Respimat® is used for

Spiolto® Respimat® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Spiriva® Respimat® (tiotropium)

What Spiriva® Respimat® is and what it is used for

What Spiriva® Respimat® is

Spiriva® Respimat® contains the active ingredient tiotropium which is a long-acting bronchodilator (long-acting muscarinic antagonist) that helps to open patients’ airways and makes it easier to get air in and out of the lungs.

What Spiriva® Respimat® is used for

COPD: Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Asthma: Spiriva® Respimat® is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

spiriva

Striverdi® Respimat® (olodaterol)

What Striverdi® Respimat® is and what it is used for

striverdi

What Striverdi® Respimat® is

Striverdi® Respimat® contains the active ingredient olodaterol which is a long-acting bronchodilator (long-acting beta2 agonist) that helps to open patients’ airways and makes it easier to get air in and out of the lungs.

What Striverdi® Respimat® is used for

Striverdi® Respimat® is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).

respimat seperator

Frequently asked questions

  • The patient may have been prescribed a refill cartridge and this should be used together with the inhaler. Each inhaler can be used with up to 6 refill cartridges
  • Not to throw the Respimat® re-usable inhaler away when the cartridge is empty.
  • The cartridge should be replaced when the indicator changes colour to red with a white arrow indicating that the cartridge is empty.
  • To get a new prescription when the dose counter changes colour to yellow

Respimat® re-usable is available as a single pack (one Respimat® re-usable inhaler plus one cartridge) and a single refill pack (one cartridge). One cartridge contains 60 puffs (30 medicinal doses).

Each re-usable inhaler may be used with up to six cartridges, after which time a new Respimat® re-usable inhaler pack should be prescribed.
There is an option within prescribing systems which allows a prescriber to choose refills.

Yes. When designing the Respimat® re-usable, only a few secondary components of the Respimat® inhaler, such as the dose indicator and the length of the body, had to be modified or added. Delivered dose (DD) and particle size distribution (PSD) of the Respimat® re-usable inhaler were compared with data from a disposable Respimat®. Performance, in terms of delivered dose and fine particle dose, was unchanged. The delivered doses over nine cartridges were also stable and consistently within the upper and lower limits of the reference inhaler.

The Respimat® re-usable is licenced for use with up to six cartridges.

Boehringer Ingelheim simplified handling, improved readability of the dose indicator and redesigned the Respimat® for re-use with multiple cartridges based on patient and physician feedback. The Respimat® re-usable also offers the potential to reduce environmental impact from re-use with up to six cartridges.

PC-GB-100905 V1 - October 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (Freephone) or PV_local_uk_ireland@boehringer-ingelheim.com
The information on this website has been created by Boehringer Ingelheim. For product information, including patient leaflets and summary of product characteristics, please see Product Information section.
PC-GB-100901 V1 - October 2020